West Pharmaceutical (WST) stock plummeted 24.11% on Thursday morning's pre-market session, following the company's weaker-than-expected guidance for 2025 due to factors like biotech customers reducing pandemic-era inventories and headwinds from a strong U.S. dollar.
The medical equipment maker forecast 2025 adjusted earnings per share of $6 to $6.20, well below analysts' average estimate of $7.44. It also projected full-year revenue between $2.88 billion and $2.91 billion, missing expectations of $3.04 billion.
West Pharma cited the ongoing impact of destocking by its biotech clients, who had built up inventories during pandemic supply chain disruptions. The company's CEO Eric Green noted that "the impact of destocking continues to moderate" but remains a challenge. A strong U.S. dollar also weighed on the outlook by impacting overseas revenues.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。